Format

Send to

Choose Destination
Sci Signal. 2009 Apr 21;2(67):pe24. doi: 10.1126/scisignal.267pe24.

The pharmacology of mTOR inhibition.

Author information

1
Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02141, USA.

Abstract

A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)-based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic.

PMID:
19383975
DOI:
10.1126/scisignal.267pe24
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center